This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Curis Reports CUDC-907 Preliminary Data From The Ongoing Phase 1 Trial At ASH 2013 Annual Meeting

Stocks in this article: CRIS

CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity

Dose escalation ongoing with intermittent oral administration schedule in patients with relapsed/refractory lymphoma or multiple myeloma

LEXINGTON, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced preliminary first-in-human results from its ongoing Phase 1 trial of CUDC-907. These data will be presented today at the 55 th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA. Intermittent oral dosing of CUDC-907 appears to be better tolerated than continuous daily dosing (QD), which demonstrated preliminary evidence of anti-tumor activity with a partial response (PR) observed in 1 patient. In addition, stable disease (SD) has been observed in 7 of 11 response-evaluable patients.  CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in a Phase 1 trial in patients with relapsed/refractory lymphoma or multiple myeloma (MM).

"We are encouraged by the preliminary results of our ongoing Phase 1 study and will further explore clinical activity signals when administering CUDC-907 on intermittent dosing schedules," said Dr. Ali Fattaey, Ph.D., Curis' President and Chief Operating Officer. "After establishing a safe and tolerable dose range for the intermittent schedules, we expect to initiate the expansion phase of this study followed by mid-stage clinical trials in one or more hematologic malignancies in the second half of 2014."

"CUDC-907's unique mechanism of action and its promising early clinical profile support further investigation in patients with aggressive lymphomas or multiple myeloma," said Dr. Jaye Viner, M.D., M.P.H, Curis' Executive Vice President and Chief Medical Officer.

The dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose, as well as preliminary anti-cancer activity of single agent       CUDC-907 in patients with relapsed/refractory lymphoma or MM. At the time of data cut-off for the ASH presentation, 13 patients had received daily (QD) or twice weekly (BIW) regimens at doses of 30 mg QD (n=7), 60 mg QD (n=3) or 60 mg BIW (n=3). More recently, investigators began enrolling patients in a third dosing schedule in which CUDC-907 is administered thrice weekly (TIW).

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs